Sign In
Buy EBS
$7.93
-0.280 (-3.41%)
At Close: Jun 03, 2026
Why Is Emergent BioSolutions (EBS) Stock Up 57% Today?
07:58am, Thursday, 02'nd May 2024
Emergent BioSolutions (NYSE: EBS ) stock is taking off on Thursday after surprising investors with strong Q1 2024 earnings results. The life sciences company reported adjusted earnings per share of 5
Emergent BioSolutions Inc. (EBS) Q1 2024 Earnings Call Transcript
09:38pm, Wednesday, 01'st May 2024
Emergent BioSolutions Inc. (NYSE:EBS ) Q1 2024 Earnings Call Transcript May 1, 2024 5:00 PM ET Company Participants Joe Papa - President and CEO Rich Lindahl - EVP and CFO Paul Williams - SVP, Product
Narcan-Maker Emergent BioSolutions to Cut 300 Jobs, Close Facilities
05:13pm, Wednesday, 01'st May 2024
Emergent BioSolutions is closing several manufacturing facilities and cutting hundreds of jobs as part of a restructuring as the company narrows its focus on products, including Narcan nasal spray.
Emergent BioSolutions Reports First Quarter 2024 Financial Results
04:57pm, Wednesday, 01'st May 2024
GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2024.
Emergent BioSolutions to lay off about 300 employees
04:38pm, Wednesday, 01'st May 2024
Emergent BioSolutions said on Wednesday that it would cut about 300 jobs across all areas of the company and shut down several manufacturing facilities as part of a restructuring plan.
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
04:10pm, Wednesday, 01'st May 2024
GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced the next phase of its new operational plan that consolidates operations, closes several manufactu
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
11:03am, Wednesday, 01'st May 2024
GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the results of a new national public opinion survey showing that more than 90 percent of Amer
Emergent BioSolutions Announces Amendment to its Existing Credit Facility
05:26pm, Tuesday, 30'th Apr 2024
GAITHERSBURG, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that it has entered into a “Consent, Waiver and Seventh Amendment” to its existing credit fa
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
08:05am, Monday, 22'nd Apr 2024
GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial res
GAITHERSBURG, Md., March 28, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) remains committed to fighting the ongoing opioid crisis by broadening access to, and awareness of, NARCAN®
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
08:05am, Monday, 25'th Mar 2024
GAITHERSBURG, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has listed “No Action Indicated” or NAI sta
Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales
01:36pm, Thursday, 07'th Mar 2024
Emergent (EBS) reports mixed earnings for fourth-quarter 2023. The company signs a forbearance agreement with its lenders, effective till April 2023-end.
Emergent BioSolutions Inc. (EBS) Q4 2023 Earnings Call Transcript
07:37pm, Wednesday, 06'th Mar 2024
Emergent BioSolutions Inc. (NYSE:EBS ) Q4 2023 Earnings Conference Call March 6, 2024 5:00 PM ET Company Participants Rich Lindahl - Executive Vice President & Chief Financial Officer Joe Papa - Presi
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
06:56pm, Wednesday, 06'th Mar 2024
Emergent Biosolutions (EBS) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.31 per share a year ago.
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
04:31pm, Wednesday, 06'th Mar 2024
GAITHERSBURG, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2023.
